Skip to main content
. 2020 Apr 28;11(17):1478–1492. doi: 10.18632/oncotarget.27539

Figure 3. Combination CDK4/6 and PIM kinase inhibition suppresses mTOR signaling and cell growth.

Figure 3

(A) DMS-53 cells were treated with the combination of PIM inhibitor PIM447 and abemaciclib or palbociclib for 2DT and cell growth was assessed by CellTiter-Glo. Curve shift analysis [66] was used to calculate a combination index (CI) as an indication of additivity or synergy between the compounds. (B) DMS-53 cells were treated with the combination of PIM inhibitor PIM447 (0.3 µM) and abemaciclib or palbociclib for 4 h and analyzed by western blot.